TY - JOUR
T1 - Thermo-responsive and biodegradable MoS2-based nanoplatform for tumor therapy and postoperative wound management
AU - Yin, Yichen
AU - Wang, Nan
AU - Hu, Bin
AU - Guo, Jiaxuan
AU - Chen, Qian
AU - Chen, Zheng
AU - Shahbazi, Mohammad Ali
AU - Agüero, Lissette
AU - Wang, Shige
AU - Li, Cheng
N1 - Publisher Copyright:
© 2025 Elsevier Inc.
PY - 2025/5/15
Y1 - 2025/5/15
N2 - Inorganic nanoparticles serve as versatile nanoplatforms for efficient cancer diagnosis and therapy. However, their limited in vivo degradability and excretion rates may lead to various adverse effects. Furthermore, the cascade-controlled release of drugs remains a challenge. In this study, we developed a free-radical triggered degradable MoS2-AIPH@LA nanoplatform for tumor photothermal and oxygen-independent thermodynamic therapy. This was achieved by loading the free radical initiator (2,2′-azobis[2-(2-imidazolin-2-yl) propane] dihydrochloride (AIPH)) onto MoS2 nanoparticles and encapsulating them with thermo-responsive lauric acid (LA). Upon laser irradiation, the hyperthermia generated by MoS2 induces cancer cell death and releases AIPH, an oxygen-independent and thermal-responsive radical initiator capable of producing toxic alkyl free radicals for tumor therapy and inhibiting bacterial growth. Importantly, these free radicals promote the degradation rate of MoS2-AIPH@LA, further facilitating a rapid AIPH release and improving the biocompatibility of the MoS2-AIPH@LA nanoplatform. In particular, the thermo-responsive nature of LA in this formulation effectively regulates the release of AIPH, thus reducing potential AIPH leakage into the bloodstream and minimizing safety risks. With its free-radical-triggered degradation and cascade-controlled release capabilities, MoS2-AIPH@LA shows significant promise for inhibiting tumor proliferation and managing postoperative bacterial infection.
AB - Inorganic nanoparticles serve as versatile nanoplatforms for efficient cancer diagnosis and therapy. However, their limited in vivo degradability and excretion rates may lead to various adverse effects. Furthermore, the cascade-controlled release of drugs remains a challenge. In this study, we developed a free-radical triggered degradable MoS2-AIPH@LA nanoplatform for tumor photothermal and oxygen-independent thermodynamic therapy. This was achieved by loading the free radical initiator (2,2′-azobis[2-(2-imidazolin-2-yl) propane] dihydrochloride (AIPH)) onto MoS2 nanoparticles and encapsulating them with thermo-responsive lauric acid (LA). Upon laser irradiation, the hyperthermia generated by MoS2 induces cancer cell death and releases AIPH, an oxygen-independent and thermal-responsive radical initiator capable of producing toxic alkyl free radicals for tumor therapy and inhibiting bacterial growth. Importantly, these free radicals promote the degradation rate of MoS2-AIPH@LA, further facilitating a rapid AIPH release and improving the biocompatibility of the MoS2-AIPH@LA nanoplatform. In particular, the thermo-responsive nature of LA in this formulation effectively regulates the release of AIPH, thus reducing potential AIPH leakage into the bloodstream and minimizing safety risks. With its free-radical-triggered degradation and cascade-controlled release capabilities, MoS2-AIPH@LA shows significant promise for inhibiting tumor proliferation and managing postoperative bacterial infection.
KW - Alkyl free radical
KW - Chemodynamic therapy
KW - Degradation
KW - MoS
KW - Thermodynamic therapy
UR - https://www.scopus.com/pages/publications/85216863295
U2 - 10.1016/j.jcis.2025.01.257
DO - 10.1016/j.jcis.2025.01.257
M3 - Article
C2 - 39914308
AN - SCOPUS:85216863295
SN - 0021-9797
VL - 686
SP - 634
EP - 649
JO - Journal of Colloid and Interface Science
JF - Journal of Colloid and Interface Science
ER -